Table of Contents

company-logo

Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Passage Bio Dividend Announcement

• Passage Bio does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Passage Bio dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Passage Bio Dividend History

Passage Bio Dividend Yield

Passage Bio current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Passage Bio stock? Use our calculator to estimate your expected dividend yield:

Passage Bio Financial Ratios

P/E ratio-0.52
PEG ratio-0.02
P/B ratio0.44
ROE-70.73%
Payout ratio0.00%
Current ratio7.67
Quick ratio7.67
Cash Ratio2.00

Passage Bio Dividend FAQ

Does Passage Bio stock pay dividends?
Passage Bio does not currently pay dividends to its shareholders.
Has Passage Bio ever paid a dividend?
No, Passage Bio has no a history of paying dividends to its shareholders. Passage Bio is not known for its dividend payments.
Why doesn't Passage Bio pay dividends?
There are several potential reasons why Passage Bio would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Passage Bio ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Passage Bio has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Passage Bio a dividend aristocrat?
Passage Bio is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Passage Bio a dividend king?
Passage Bio is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Passage Bio a dividend stock?
No, Passage Bio is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Passage Bio stocks?
To buy Passage Bio you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Passage Bio stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.